Free Trial
NASDAQ:MTVA

MetaVia (MTVA) Stock Price, News & Analysis

MetaVia logo
$0.65 +0.01 (+1.72%)
As of 08/22/2025 03:27 PM Eastern

About MetaVia Stock (NASDAQ:MTVA)

Key Stats

Today's Range
$0.61
$0.66
50-Day Range
$0.60
$0.74
52-Week Range
$0.56
$4.32
Volume
84,184 shs
Average Volume
170,644 shs
Market Capitalization
$15.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

MetaVia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

MTVA MarketRank™: 

MetaVia scored higher than 42% of companies evaluated by MarketBeat, and ranked 647th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MetaVia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MetaVia has received no research coverage in the past 90 days.

  • Read more about MetaVia's stock forecast and price target.
  • Earnings Growth

    Earnings for MetaVia are expected to grow in the coming year, from ($3.90) to ($1.64) per share.

  • Price to Book Value per Share Ratio

    MetaVia has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about MetaVia's valuation and earnings.
  • Short Interest

    There is no current short interest data available for MTVA.
  • Dividend Yield

    MetaVia does not currently pay a dividend.

  • Dividend Growth

    MetaVia does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MTVA.
  • News Sentiment

    MetaVia has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for MetaVia this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for MTVA on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added MetaVia to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MetaVia insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.80% of the stock of MetaVia is held by insiders.

  • Percentage Held by Institutions

    Only 1.37% of the stock of MetaVia is held by institutions.

  • Read more about MetaVia's insider trading history.
Receive MTVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter.

MTVA Stock News Headlines

What is Zacks Small Cap's Estimate for MetaVia Q3 Earnings?
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.tc pixel
MetaVia Extends Phase 1 Trial for Obesity Drug
See More Headlines

MTVA Stock Analysis - Frequently Asked Questions

MetaVia's stock was trading at $2.03 at the beginning of the year. Since then, MTVA stock has decreased by 68.0% and is now trading at $0.65.

MetaVia Inc. (NASDAQ:MTVA) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.06.

Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/07/2025
Today
8/23/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTVA
CIK
1638287
Employees
8
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$3.00
Potential Upside/Downside
+1,053.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.59 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-212.00%
Return on Assets
-107.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.08
Quick Ratio
2.08

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
1.63

Miscellaneous

Outstanding Shares
24,200,000
Free Float
24,004,000
Market Cap
$15.73 million
Optionable
N/A
Beta
0.26
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:MTVA) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners